Nivolumab in relapsed/refractory Hodgkin Lymphoma patients, single center experiences

• Main Authors: Ramazan Acar, Murat Yildirim
• Format: Article
• Language: English
• Published: Society of TURAZ AKADEMI 2020-12-01
• Series: Medicine Science
• Subjects: nivolumab; hodgkin lymphoma; immunotherapy
• Online Access: http://www.ejmanager.com/fulltextpdf.php?mno=119705

Hodgkin Lymphoma (HL) is one of the hematological malignancies where the inflammatory process is quite high, immunotherapy agents are frequently used and successful results are obtained. We aimed to show real-life data on health outcomes in adult patients withrecurrent or refractory HL who received nivolumab (immune checkpoint inhibitory). We analyzed the data of 15 patients who received nivolumab after or before high dose chemotherapy (HDCT) for relapsed or refractory HL from 2010 to 2020. Overall response rate (ORR), overall survival (OS) and progression-free survival (PFS) of the patients were evaluated. 15 patients were observed in this study. The mean age of the study group was 26.9 ±10.9 years. 40% of the patients were female (n=6). Overall response rate (ORR) was 80 %. The median overall survival (OS) and progression-free survival (PFS) were 50.7 months (95% CI: 37.2-64.2) and 46.2 months (95% CI: 32.9-59.5), respectively. 1-year OS and PFS rates were 90.9% and %88.2, respectively. 5-year OS rate was 67.3%. Nivolumab treatment is a safe, effective and excellent treatment option for relapsed or refractory adult HL patients with a good ORR, OS and PFS time. [Med-Science 2020; 9(4.000): 1004-7]